List of Tables
Table 1. Global Antisense Oligonucleotide Therapy for the Nervous System Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Table 2. Global Antisense Oligonucleotide Therapy for the Nervous System Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Table 3. Global Antisense Oligonucleotide Therapy for the Nervous System Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 4. Global Antisense Oligonucleotide Therapy for the Nervous System Revenue by Region (2020-2025) & (US$ Million)
Table 5. Global Antisense Oligonucleotide Therapy for the Nervous System Revenue by Region (2026-2031) & (US$ Million)
Table 6. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 7. Global Antisense Oligonucleotide Therapy for the Nervous System Revenue by Players (2020-2025) & (US$ Million)
Table 8. Global Antisense Oligonucleotide Therapy for the Nervous System Revenue Market Share by Players (2020-2025)
Table 9. Global Key Players’Ranking Shift (2023 vs. 2024) (Based on Revenue)
Table 10. Global Antisense Oligonucleotide Therapy for the Nervous System by Player Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Antisense Oligonucleotide Therapy for the Nervous System as of 2024)
Table 11. Global Antisense Oligonucleotide Therapy for the Nervous System Average Gross Margin (%) by Player (2020 VS 2024)
Table 12. Global Antisense Oligonucleotide Therapy for the Nervous System Companies Headquarters
Table 13. Global Antisense Oligonucleotide Therapy for the Nervous System Market Concentration Ratio (CR5 and HHI)
Table 14. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
Table 15. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 16. Global Antisense Oligonucleotide Therapy for the Nervous System Revenue by Type (2020-2025) & (US$ Million)
Table 17. Global Antisense Oligonucleotide Therapy for the Nervous System Revenue by Type (2026-2031) & (US$ Million)
Table 18. Key Product Attributes and Differentiation
Table 19. Global Antisense Oligonucleotide Therapy for the Nervous System Revenue by Application (2020-2025) & (US$ Million)
Table 20. Global Antisense Oligonucleotide Therapy for the Nervous System Revenue by Application (2026-2031) & (US$ Million)
Table 21. Antisense Oligonucleotide Therapy for the Nervous System High-Growth Sectors Demand CAGR (2024-2031)
Table 22. Top Customers by Region
Table 23. Top Customers by Application
Table 24. North America Antisense Oligonucleotide Therapy for the Nervous System Growth Accelerators and Market Barriers
Table 25. North America Antisense Oligonucleotide Therapy for the Nervous System Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 26. Europe Antisense Oligonucleotide Therapy for the Nervous System Growth Accelerators and Market Barriers
Table 27. Europe Antisense Oligonucleotide Therapy for the Nervous System Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 28. Asia-Pacific Antisense Oligonucleotide Therapy for the Nervous System Growth Accelerators and Market Barriers
Table 29. Asia-Pacific Antisense Oligonucleotide Therapy for the Nervous System Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 30. Central and South America Antisense Oligonucleotide Therapy for the Nervous System Investment Opportunities and Key Challenges
Table 31. Central and South America Antisense Oligonucleotide Therapy for the Nervous System Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 32. Middle East and Africa Antisense Oligonucleotide Therapy for the Nervous System Investment Opportunities and Key Challenges
Table 33. Middle East and Africa Antisense Oligonucleotide Therapy for the Nervous System Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 34. Ionis Pharmaceuticals Corporation Information
Table 35. Ionis Pharmaceuticals Description and Major Businesses
Table 36. Ionis Pharmaceuticals Product Features and Attributes
Table 37. Ionis Pharmaceuticals Revenue (US$ Million) and Gross Margin (2020-2025)
Table 38. Ionis Pharmaceuticals Revenue Proportion by Product in 2024
Table 39. Ionis Pharmaceuticals Revenue Proportion by Application in 2024
Table 40. Ionis Pharmaceuticals Revenue Proportion by Geographic Area in 2024
Table 41. Ionis Pharmaceuticals Antisense Oligonucleotide Therapy for the Nervous System SWOT Analysis
Table 42. Ionis Pharmaceuticals Recent Developments
Table 43. Biogen Corporation Information
Table 44. Biogen Description and Major Businesses
Table 45. Biogen Product Features and Attributes
Table 46. Biogen Revenue (US$ Million) and Gross Margin (2020-2025)
Table 47. Biogen Revenue Proportion by Product in 2024
Table 48. Biogen Revenue Proportion by Application in 2024
Table 49. Biogen Revenue Proportion by Geographic Area in 2024
Table 50. Biogen Antisense Oligonucleotide Therapy for the Nervous System SWOT Analysis
Table 51. Biogen Recent Developments
Table 52. Sobi Corporation Information
Table 53. Sobi Description and Major Businesses
Table 54. Sobi Product Features and Attributes
Table 55. Sobi Revenue (US$ Million) and Gross Margin (2020-2025)
Table 56. Sobi Revenue Proportion by Product in 2024
Table 57. Sobi Revenue Proportion by Application in 2024
Table 58. Sobi Revenue Proportion by Geographic Area in 2024
Table 59. Sobi Antisense Oligonucleotide Therapy for the Nervous System SWOT Analysis
Table 60. Sobi Recent Developments
Table 61. Nippon Shinyaku Corporation Information
Table 62. Nippon Shinyaku Description and Major Businesses
Table 63. Nippon Shinyaku Product Features and Attributes
Table 64. Nippon Shinyaku Revenue (US$ Million) and Gross Margin (2020-2025)
Table 65. Nippon Shinyaku Revenue Proportion by Product in 2024
Table 66. Nippon Shinyaku Revenue Proportion by Application in 2024
Table 67. Nippon Shinyaku Revenue Proportion by Geographic Area in 2024
Table 68. Nippon Shinyaku Antisense Oligonucleotide Therapy for the Nervous System SWOT Analysis
Table 69. Nippon Shinyaku Recent Developments
Table 70. Jazz Pharmaceuticals Corporation Information
Table 71. Jazz Pharmaceuticals Description and Major Businesses
Table 72. Jazz Pharmaceuticals Product Features and Attributes
Table 73. Jazz Pharmaceuticals Revenue (US$ Million) and Gross Margin (2020-2025)
Table 74. Jazz Pharmaceuticals Revenue Proportion by Product in 2024
Table 75. Jazz Pharmaceuticals Revenue Proportion by Application in 2024
Table 76. Jazz Pharmaceuticals Revenue Proportion by Geographic Area in 2024
Table 77. Jazz Pharmaceuticals Antisense Oligonucleotide Therapy for the Nervous System SWOT Analysis
Table 78. Jazz Pharmaceuticals Recent Developments
Table 79. Raw Materials Key Suppliers
Table 80. Distributors List
Table 81. Market Trends and Market Evolution
Table 82. Market Drivers and Opportunities
Table 83. Market Challenges, Risks, and Restraints
Table 84. Research Programs/Design for This Report
Table 85. Key Data Information from Secondary Sources
Table 86. Key Data Information from Primary Sources
List of Figures
Figure 1. Antisense Oligonucleotide Therapy for the Nervous System Product Picture
Figure 2. Global Antisense Oligonucleotide Therapy for the Nervous System Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Figure 3. Intrathecal Injection Product Picture
Figure 4. Intravenous Injections Product Picture
Figure 5. Other Product Picture
Figure 6. Global Antisense Oligonucleotide Therapy for the Nervous System Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Figure 7. Neuromuscular Diseases
Figure 8. hATTR
Figure 9. Other
Figure 10. Antisense Oligonucleotide Therapy for the Nervous System Report Years Considered
Figure 11. Global Antisense Oligonucleotide Therapy for the Nervous System Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 12. Global Antisense Oligonucleotide Therapy for the Nervous System Revenue (2020-2031) & (US$ Million)
Figure 13. Global Antisense Oligonucleotide Therapy for the Nervous System Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Figure 14. Global Antisense Oligonucleotide Therapy for the Nervous System Revenue Market Share by Region (2020-2031)
Figure 15. Global Antisense Oligonucleotide Therapy for the Nervous System Revenue Market Share Ranking (2024)
Figure 16. Tier Distribution by Revenue Contribution (2020 VS 2024)
Figure 17. Intrathecal Injection Revenue Market Share by Player in 2024
Figure 18. Intravenous Injections Revenue Market Share by Player in 2024
Figure 19. Other Revenue Market Share by Player in 2024
Figure 20. Global Antisense Oligonucleotide Therapy for the Nervous System Revenue Market Share by Type (2020-2031)
Figure 21. Global Antisense Oligonucleotide Therapy for the Nervous System Revenue Market Share by Application (2020-2031)
Figure 22. North America Antisense Oligonucleotide Therapy for the Nervous System Revenue YoY (2020-2031) & (US$ Million)
Figure 23. North America Top 5 Players Antisense Oligonucleotide Therapy for the Nervous System Revenue (US$ Million) in 2024
Figure 24. North America Antisense Oligonucleotide Therapy for the Nervous System Revenue (US$ Million) by Type (2020 - 2031)
Figure 25. North America Antisense Oligonucleotide Therapy for the Nervous System Revenue (US$ Million) by Application (2020-2031)
Figure 26. US Antisense Oligonucleotide Therapy for the Nervous System Revenue (2020-2031) & (US$ Million)
Figure 27. Canada Antisense Oligonucleotide Therapy for the Nervous System Revenue (2020-2031) & (US$ Million)
Figure 28. Mexico Antisense Oligonucleotide Therapy for the Nervous System Revenue (2020-2031) & (US$ Million)
Figure 29. Europe Antisense Oligonucleotide Therapy for the Nervous System Revenue YoY (2020-2031) & (US$ Million)
Figure 30. Europe Top 5 Players Antisense Oligonucleotide Therapy for the Nervous System Revenue (US$ Million) in 2024
Figure 31. Europe Antisense Oligonucleotide Therapy for the Nervous System Revenue (US$ Million) by Type (2020-2031)
Figure 32. Europe Antisense Oligonucleotide Therapy for the Nervous System Revenue (US$ Million) by Application (2020-2031)
Figure 33. Germany Antisense Oligonucleotide Therapy for the Nervous System Revenue (2020-2031) & (US$ Million)
Figure 34. France Antisense Oligonucleotide Therapy for the Nervous System Revenue (2020-2031) & (US$ Million)
Figure 35. U.K. Antisense Oligonucleotide Therapy for the Nervous System Revenue (2020-2031) & (US$ Million)
Figure 36. Italy Antisense Oligonucleotide Therapy for the Nervous System Revenue (2020-2031) & (US$ Million)
Figure 37. Russia Antisense Oligonucleotide Therapy for the Nervous System Revenue (2020-2031) & (US$ Million)
Figure 38. Asia-Pacific Antisense Oligonucleotide Therapy for the Nervous System Revenue YoY (2020-2031) & (US$ Million)
Figure 39. Asia-Pacific Top 8 Players Antisense Oligonucleotide Therapy for the Nervous System Revenue (US$ Million) in 2024
Figure 40. Asia-Pacific Antisense Oligonucleotide Therapy for the Nervous System Revenue (US$ Million) by Type (2020-2031)
Figure 41. Asia-Pacific Antisense Oligonucleotide Therapy for the Nervous System Revenue (US$ Million) by Application (2020-2031)
Figure 42. Indonesia Antisense Oligonucleotide Therapy for the Nervous System Revenue (2020-2031) & (US$ Million)
Figure 43. Japan Antisense Oligonucleotide Therapy for the Nervous System Revenue (2020-2031) & (US$ Million)
Figure 44. South Korea Antisense Oligonucleotide Therapy for the Nervous System Revenue (2020-2031) & (US$ Million)
Figure 45. Australia Antisense Oligonucleotide Therapy for the Nervous System Revenue (2020-2031) & (US$ Million)
Figure 46. India Antisense Oligonucleotide Therapy for the Nervous System Revenue (2020-2031) & (US$ Million)
Figure 47. Indonesia Antisense Oligonucleotide Therapy for the Nervous System Revenue (2020-2031) & (US$ Million)
Figure 48. Vietnam Antisense Oligonucleotide Therapy for the Nervous System Revenue (2020-2031) & (US$ Million)
Figure 49. Malaysia Antisense Oligonucleotide Therapy for the Nervous System Revenue (2020-2031) & (US$ Million)
Figure 50. Philippines Antisense Oligonucleotide Therapy for the Nervous System Revenue (2020-2031) & (US$ Million)
Figure 51. Singapore Antisense Oligonucleotide Therapy for the Nervous System Revenue (2020-2031) & (US$ Million)
Figure 52. Central and South America Antisense Oligonucleotide Therapy for the Nervous System Revenue YoY (2020-2031) & (US$ Million)
Figure 53. Central and South America Top 5 Players Antisense Oligonucleotide Therapy for the Nervous System Revenue (US$ Million) in 2024
Figure 54. Central and South America Antisense Oligonucleotide Therapy for the Nervous System Revenue (US$ Million) by Type (2020-2031)
Figure 55. Central and South America Antisense Oligonucleotide Therapy for the Nervous System Revenue (US$ Million) by Application (2020-2031)
Figure 56. Brazil Antisense Oligonucleotide Therapy for the Nervous System Revenue (2020-2025) & (US$ Million)
Figure 57. Argentina Antisense Oligonucleotide Therapy for the Nervous System Revenue (2020-2025) & (US$ Million)
Figure 58. Middle East and Africa Antisense Oligonucleotide Therapy for the Nervous System Revenue YoY (2020-2031) & (US$ Million)
Figure 59. Middle East and Africa Top 5 Players Antisense Oligonucleotide Therapy for the Nervous System Revenue (US$ Million) in 2024
Figure 60. South America Antisense Oligonucleotide Therapy for the Nervous System Revenue (US$ Million) by Type (2020-2031)
Figure 61. Middle East and Africa Antisense Oligonucleotide Therapy for the Nervous System Revenue (US$ Million) by Application (2020-2031)
Figure 62. GCC Countries Antisense Oligonucleotide Therapy for the Nervous System Revenue (2020-2025) & (US$ Million)
Figure 63. Israel Antisense Oligonucleotide Therapy for the Nervous System Revenue (2020-2025) & (US$ Million)
Figure 64. Egypt Antisense Oligonucleotide Therapy for the Nervous System Revenue (2020-2025) & (US$ Million)
Figure 65. South Africa Antisense Oligonucleotide Therapy for the Nervous System Revenue (2020-2025) & (US$ Million)
Figure 66. Antisense Oligonucleotide Therapy for the Nervous System Industry Chain Mapping
Figure 67. Channels of Distribution (Direct Vs Distribution)
Figure 68. Bottom-up and Top-down Approaches for This Report
Figure 69. Data Triangulation
Figure 70. Key Executives Interviewed
